Nikang Therapeutics, Inc.
Clinical trials sponsored by Nikang Therapeutics, Inc., explained in plain language.
-
New pill targets Hard-to-Treat cancers in early human trial
Disease control Recruiting nowThis early-phase study tests an experimental pill, NKT3964, designed to break down a protein (CDK2) that helps cancer cells grow. About 150 adults with advanced or metastatic solid tumors (including ovarian, endometrial, breast, gastric, and lung cancers) that have stopped respon…
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New pill shows promise in early trial for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new oral drug, NKT5097, in 205 adults with advanced solid tumors that have not responded to other treatments. The main goals are to find the safest dose and understand side effects. The study focuses on breast cancer and other tumors with specific g…
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated May 12, 2026 13:39 UTC